Avtor/Urednik		Gabryelewicz, Antoni; Czajkowski, Andrzej; Dzieniszewski, Jan; Janicki, Wlodzimierz; Merlicz, Krzysztof; Jaroszewicz, Mariusz; Popiela, Tadeusz; Legutko, Janusz; Bielanski, Wladyslaw; Ivanuša, Marijan
Naslov		The effectiveness of lansoprazole, clarithromycin and amoxicillin in eradication of Helicobacter pylori in patients with duodenal peptic ulcer
Tip		članek
Vir		Gastroenterologia
Vol. in št.		Letnik 1, št. 4
Leto izdaje		2000
Obseg		str. 194-202
Jezik		eng
Abstrakt		The study was performed with the aim to establish the efficacy and safety of lansoprazole- based triple therapy in the eradication of Helicobacter pylori in patients with active duodenal ulcer, and to assess healing and recurrence of peptic ulcer and reinfection rates during a follow up period of 12 monts. The influence of the prolonged therapy with lansoprazole was studied. The double-blind, randomized study was carried out in four centers in Poland (Bialystok, Warsaw, Szczecin, Krakow). Patients (n=119) were treated for 7 days with lansoprazole 30 mg, clarithromycin 500 mg and amoxicillin 1000 mg twice daily (group A) or had the same therapy during the first 7 days and the treatment was thenafter prolonged for additional 7 days - with lansoprazole 30 mg once a day (in the morning). Patients were endoscopically examined prior to the treatment, after 6 weeks, 6 months and 12 months. Helicobacter pylori test were performed during these control visita (CLO test, histology, breath test). There were no statistically significant differences between the treated groups. The ulcer healing rate in group A was 93%, 98% and 98% at 6 weeks, 6 months and 12 months and in group P 94%, 95% and 100%, respectively. There was no statistically significant difference in Helicobacter pylori status between two groups. The overall eradication arte after 6 weeks was 84%. There were 88% and 89% Helicobacter pylori-negative patients after 6 and 12 months. Side effects were mostly mild.
Deskriptorji		PEPTIC ULCER HELICOBACTER PYLORI CLARITHROMYCIN AMOXICILLIN RECURRENCE CLINICAL TRIALS DRUG THERAPY, COMBINATION TREATMENT OUTCOME PROTON PUMP